Tag Archives | clinical diagnostics

Slower Growth in Diagnostics Stocks Except for NexGen Sequencing and Molecular

New technologies in diagnostics and tools are driving growth: NexGen sequencing, molecular and “point-of-care” testing platforms and veterinary testing. M&A and consolidation should continue. The sector is a laggard due to slowing  sales and earnings growth vs forecasts. Rayno Clinical Diagnostics Portfolio Update We initiated coverage of Clinical Diagnostic and Life Science Tools stocks in […]

Continue Reading 0

Rayno Dx and Tools: Update EXAS

Valuation Does Matter If Revenue Growth Slows Last week we posted a YTD summary of our diagnostics and tools focus stocks. Three stocks that are up over one year but have been weak in 2015. We said that revenue guidance and technicals will be important for: Exact Sciences (EXAS), Genomic Health (GHDX) and Neogen (NEOG). […]

Continue Reading 0

Rayno Dx and Tools Portfolio: CSII HOLX ILMN TMO Stellar Performers

Solid  earnings reports-All of Our Picks Are Strong Holds But Strong Dollar a Factor in 2105 Cardiovascular Systems (CSII) Stock Soars 15% On Strong Revenues Interventional treatments for cardiovascular disease Q2 Revenues soared 38% to $44.7M compared to previous fiscal Q2 2014. Fiscal Q2 2105 loss was $5.3M or (0.17) per share. Hologic (HOLX) Beats […]

Continue Reading 0

JPMorgan Conference #3: Emerging Clinical Dx Companies- AXDX, GNMK

Next Generation Clinical Diagnostic Systems We sat in on presentations for two innovative clinical diagnostic companies that have platform products serving big potential markets. Although it may be early to buy these stocks now they should be on your watch list for the new product revenue ramp up. Solutions For The Global Challenge of Drug […]

Continue Reading 0

2015 Biotech Stock Preview: Rhythms of the “PermaBull”

2015: Another Good Year Unless “Something Happens” Life Science stocks had another big year in 2014 up 48% tracking gains for the overall healthcare sector up 35%. Over 10 years the return is 300%! The move up was not a straight line as there were  two major corrections in April 2014 after the Q1 “bio-bubble” […]

Continue Reading 0